May 26, 2022 | Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic...
April 28, 2022 | Tvardi Therapeutics to Participate in Morgan Stanley Private Company Biotech...
April 21, 2022 | Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for...
Tvardi Therapeutics is a private, clinical stage biotechnology company developing a new class of breakthrough medicines for diverse cancers and chronic inflammatory and fibrotic diseases. Tvardi is focused on the development of orally delivered, small molecule inhibitors of STAT3, a key signaling molecule positioned at the intersection of many disease pathways.
Developing novel inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis.
Tvardi Therapeutics is led by a group of experienced entrepreneurs, innovative scientists & dedicated physicians.
Tvardi Named 2021 Winner of Fierce 15 Biotech
Fierce Biotech has named Tvardi Therapeutics as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising biotechnology companies in the industry.